Literature DB >> 11786218

Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1.

A Boutajangout1, K Leroy, N Touchet, M Authelet, V Blanchard, G Tremp, L Pradier, J P Brion.   

Abstract

Neurofibrillary tangles, composed of tau proteins, are a key lesion observed in sporadic forms of Alzheimer's disease and in familial forms associated with mutations of presenilin-1 (PS1). We have generated a double transgenic mouse line expressing a human tau isoform and a mutated form of PS1 (M146L) in neurons. Increased expression of the PS1 holoprotein was observed in the tau/PS1 transgenic mice and the proteolytic fragments of PS1 did not appear to be modified. A somatodendritic accumulation of the transgenic tau and an increase in tau phosphorylation were observed in both tau- and tau/PS1 transgenic mice. Neurofibrillary tangles were not observed in animals analyzed up to 17 months. Immunoprecipitation of tau from brain homogenates demonstrated its binding with active glycogen synthase kinase-3beta in control, tau- and tau/PS1 transgenic lines. These results suggest that overexpression of this Alzheimer mutant PS1 in vivo is not by itself sufficient to induce the formation of neurofibrillary tangles, even in neurons co-expressing and accumulating a human tau isoform.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786218     DOI: 10.1016/s0304-3940(01)02461-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

Review 1.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

2.  Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.

Authors:  Allal Boutajangout; Johanna Ingadottir; Peter Davies; Einar M Sigurdsson
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

3.  Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.

Authors:  Allal Boutajangout; David Quartermain; Einar M Sigurdsson
Journal:  J Neurosci       Date:  2010-12-08       Impact factor: 6.167

4.  Increased tauopathy drives microglia-mediated clearance of beta-amyloid.

Authors:  Wesley Chen; Edsel A Abud; Stephen T Yeung; Anita Lakatos; Trevor Nassi; Jane Wang; David Blum; Luc Buée; Wayne W Poon; Mathew Blurton-Jones
Journal:  Acta Neuropathol Commun       Date:  2016-06-23       Impact factor: 7.801

5.  Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice.

Authors:  Karelle Leroy; Alexis Bretteville; Katharina Schindowski; Emmanuel Gilissen; Michèle Authelet; Robert De Decker; Zehra Yilmaz; Luc Buée; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

Review 6.  Vaccination as a therapeutic approach to Alzheimer's disease.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

7.  Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide--relevance in Alzheimer's disease.

Authors:  Carlos A Ribeiro; Maria João Saraiva; Isabel Cardoso
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

8.  The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer's disease.

Authors:  Alessandro Padovani; Nicola Gilberti; Barbara Borroni
Journal:  Int J Alzheimers Dis       Date:  2011-02-21

9.  Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice.

Authors:  Michael A Mastrangelo; William J Bowers
Journal:  BMC Neurosci       Date:  2008-08-12       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.